Mersana Therapeutics has a twelve month low of $0.49 and a twelve month high of $6.28. The company has a market cap of $79.47 million, a P/E ratio of -1.05 and a beta of 1.43.
On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback